31.01.2020 • News

Air Liquide Talks to Messer on Assets Sale

Air Liquide Talks to Messer on Assets Sale (c) Messer
Air Liquide Talks to Messer on Assets Sale (c) Messer

French industrial gases group Air Liquide has announced it is talking exclusively to German gases rival Messer about selling its entities in the Czech Republic and Slovakia.

Air Liquide said the decision illustrates its strategy to regularly review its asset portfolio and focus its geographic expansion on key regions.

The respective companies to be sold started operating in Slovakia in 2000 and a year later in the Czech Republic. Both locations employ a total of 53 people with offices in Trnava and Prague.

Last year, Messer, in a joint venture with private equity firm CVC Capital Partners Fund VII, bought most of Linde’s North American industrial gas assets along with some activities in South America. Linde had to sell the operations to get clearance from the US Federal Trade Commission for its merger with Praxair.

The German gases group has said it plans to invest about $3.6 billion in the Messer Industries joint venture. Last September, six months after it closed the purchase of Linde’s assets, the company announced it would spend $38 million to build a new air separation plant in Indianapolis, Indiana.

The Indiana facility, which will produce oxygen, nitrogen and argon, is planned to start up in early 2021. It will supply industrial- and medical-grade gases to the healthcare, chemical and food sectors as well as the glass and metal industries.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read